SG Americas Securities LLC Buys 17,423 Shares of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)

SG Americas Securities LLC raised its stake in shares of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) by 84.7% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 37,988 shares of the biopharmaceutical company’s stock after purchasing an additional 17,423 shares during the period. SG Americas Securities LLC’s holdings in Intercept Pharmaceuticals were worth $564,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Bank of America Corp DE boosted its holdings in shares of Intercept Pharmaceuticals by 0.3% during the 2nd quarter. Bank of America Corp DE now owns 237,419 shares of the biopharmaceutical company’s stock valued at $4,741,000 after purchasing an additional 775 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in shares of Intercept Pharmaceuticals by 6.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 16,446 shares of the biopharmaceutical company’s stock valued at $328,000 after buying an additional 1,012 shares in the last quarter. ProShare Advisors LLC raised its position in shares of Intercept Pharmaceuticals by 15.0% during the 2nd quarter. ProShare Advisors LLC now owns 13,227 shares of the biopharmaceutical company’s stock valued at $264,000 after buying an additional 1,730 shares in the last quarter. Advisory Services Network LLC purchased a new stake in shares of Intercept Pharmaceuticals during the 2nd quarter valued at about $42,000. Finally, Swiss National Bank raised its position in shares of Intercept Pharmaceuticals by 3.7% during the 2nd quarter. Swiss National Bank now owns 61,900 shares of the biopharmaceutical company’s stock valued at $1,236,000 after buying an additional 2,200 shares in the last quarter. 75.53% of the stock is owned by institutional investors and hedge funds.

Shares of NASDAQ:ICPT opened at $17.76 on Friday. The firm has a market cap of $524.75 million, a PE ratio of -5.48 and a beta of 1.42. The firm’s 50 day simple moving average is $16.83 and its 200-day simple moving average is $16.50. Intercept Pharmaceuticals, Inc. has a one year low of $11.60 and a one year high of $38.94.

Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its earnings results on Wednesday, November 3rd. The biopharmaceutical company reported ($0.11) EPS for the quarter, topping the Zacks’ consensus estimate of ($1.00) by $0.89. The company had revenue of $92.80 million for the quarter, compared to analysts’ expectations of $83.04 million. The business’s revenue was up 16.7% compared to the same quarter last year. During the same period last year, the business posted ($2.01) earnings per share. On average, sell-side analysts expect that Intercept Pharmaceuticals, Inc. will post -3.31 EPS for the current fiscal year.

Several brokerages have recently issued reports on ICPT. BMO Capital Markets restated a “hold” rating and set a $22.00 target price on shares of Intercept Pharmaceuticals in a research report on Monday, November 8th. Jefferies Financial Group restated a “hold” rating and set a $19.00 target price on shares of Intercept Pharmaceuticals in a research report on Friday, November 5th. B. Riley upgraded shares of Intercept Pharmaceuticals from a “neutral” rating to a “buy” rating and upped their target price for the company from $25.00 to $30.00 in a research report on Monday, January 10th. Raymond James upped their target price on shares of Intercept Pharmaceuticals from $40.00 to $44.00 and gave the company an “outperform” rating in a research report on Thursday, November 4th. Finally, Zacks Investment Research lowered shares of Intercept Pharmaceuticals from a “hold” rating to a “sell” rating and set a $17.00 price objective on the stock. in a research report on Thursday. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $29.19.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc operates as a biopharmaceutical company. The firm engages in the research, development and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline includes OCALIVA which is used for the treatment of biliary cholangitis, nonalcoholic steatohepatitis, sclerosing cholangitis and biliary atresia.

Further Reading: What is Considered a Good Return on Equity (ROE)?

Want to see what other hedge funds are holding ICPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT).

Institutional Ownership by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.